US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Turn Therapeutics (Direct Listing)

9.82

+0.22002.29%

Post-market: 9.10-0.7200-7.33%19:30 EDT

Volume:43.21K

Turnover:421.07K

Market Cap:292.52M

PE:-33.62

High:10.29

Open:9.60

Low:9.28

Close:9.60

52wk High:26.50

52wk Low:2.57

Shares:29.79M

Float Shares:11.41M

Volume Ratio:0.89

T/O Rate:0.38%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2921

EPS(LYR):-0.1152

ROE:-686.28%

ROA:-50.27%

PB:425.86

PE(LYR):-85.21

Loading ...

Overview Company News Filings

Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results

Turn announces interim analysis findings from Phase 2 trial of GX-03

Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data

Turn Therapeutics says Phase 2 interim data show GX-03 hits 70.4% EASI-75 at week 4 in atopic dermatitis trial

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy From Phase 2 Gx-03 Trial in Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS

Turn Therapeutics - Interim Analysis Leads to Trial Enrollment and Endpoint Refinement

THOMSON REUTERS

Turn Therapeutics - No Treatment-Related Serious Adverse Events or Discontinuations Reported in Interim Analysis

THOMSON REUTERS

Turn Therapeutics announces peer-reviewed article on GX-03

Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment

Turn Therapeutics CEO to Present at Jefferies Conference

Turn Therapeutics CEO presents at Jefferies Global Healthcare Conference

Turn Therapeutics Appoints Former FDA Chief to Lead GX-03

Turn appoints Hahn as Executive Clinical, Regulatory Lead for GX-03

Turn Therapeutics names former FDA chief Hahn executive clinical, regulatory lead

BRIEF-Turn Therapeutics Reports First Quarter 2026 Financial Results

Turn Therapeutics posts corporate presentation on GX-03 topical immunomodulator for atopic dermatitis

Turn Therapeutics Q1 FY26 net loss widens to $970,972; G&A expenses rise to $1.14 million

Press Release: Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Turn Therapeutics FY25 net loss widens to $3.2 million; G&A expenses climb to $5.6 million

Turn Therapeutics Secures Growth Capital to Advance Dermatology

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/TTRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","market":"US","secType":"STK","nameCN":"Turn Therapeutics (Direct Listing)","latestPrice":9.82,"timestamp":1788292800000,"preClose":9.6,"halted":0,"volume":43211,"hourTrading":{"tag":"盘后","latestPrice":9.1,"preClose":9.82,"latestTime":"19:30 EDT","volume":2433,"amount":23110.635,"timestamp":1788305406535,"change":-0.72,"changeRate":-0.07332,"amplitude":0.07332},"delay":0,"changeRate":0.022916666666666734,"floatShares":11408100,"shares":29788000,"eps":-0.292051,"marketStatus":"Not Yet Opened","change":0.22,"latestTime":"09-01 16:00:00 EDT","open":9.6,"high":10.285,"low":9.28,"amount":421071.274729,"amplitude":0.104688,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.292051,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":0,"adr":0,"listingDate":1759896000000,"exchange":"NASDAQ","adjPreClose":9.6,"postHourTrading":{"tag":"盘后","latestPrice":9.1,"preClose":9.82,"latestTime":"19:30 EDT","volume":2433,"amount":23110.635,"timestamp":1788305406535,"change":-0.72,"changeRate":-0.07332,"amplitude":0.07332},"volumeRatio":0.890053},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","floatShares":11408100,"roa":"-50.27%","roe":"-686.28%","lyrEps":-0.115242,"volumeRatio":0.890053,"shares":29788000,"dividePrice":0,"high":10.285,"amplitude":0.104688,"preClose":9.6,"low":9.28,"week52Low":2.5701,"pbRate":"425.86","week52High":26.5,"institutionHeld":0,"latestPrice":9.82,"eps":-0.292051,"divideRate":0,"volume":43211,"delay":0,"ttmEps":-0.292051,"open":9.6,"prevYearClose":3.94,"prevWeekClose":9.84,"prevMonthClose":9.6,"prevQuarterClose":7.3,"fiveDayClose":9.73,"twentyDayClose":9.52,"sixtyDayClose":5.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"TTRX","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2026-05-11","symbol":"TTRX","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1784606400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTRX","date":"2026-08-31","current":-33.624264,"percent":0.509009,"low":-100.764104,"twenty":-53.744961,"median":-34.825901,"eighty":-27.147139,"high":-21.019642,"avg":-40.560507,"sd":16.089955,"marketCap":293114313},"quantilePoints":[{"date":"2025-10-10","current":-100.764104,"twenty":-95.944951,"median":-88.716222,"eighty":-81.487493,"marketCap":257809999},{"date":"2025-10-17","current":-61.772777,"twenty":-80.611283,"median":-71.301556,"eighty":-62.49565,"marketCap":158048738},{"date":"2025-10-24","current":-54.215469,"twenty":-75.594983,"median":-58.815569,"eighty":-54.127848,"marketCap":138712988},{"date":"2025-10-31","current":-57.391729,"twenty":-70.118673,"median":-57.391729,"eighty":-54.25928,"marketCap":146839608},{"date":"2025-11-07","current":-46.548635,"twenty":-64.664269,"median":-55.529784,"eighty":-49.111548,"marketCap":119097010},{"date":"2025-11-14","current":-44.796216,"twenty":-60.918473,"median":-54.215469,"eighty":-46.701972,"marketCap":114613358},{"date":"2025-11-21","current":-21.019642,"twenty":-57.501255,"median":-52.517813,"eighty":-44.182869,"marketCap":79796445},{"date":"2025-11-28","current":-27.302265,"twenty":-57.501255,"median":-48.301054,"eighty":-27.302265,"marketCap":103647044},{"date":"2025-12-05","current":-32.964383,"twenty":-57.391729,"median":-47.315318,"eighty":-27.302265,"marketCap":125142027},{"date":"2025-12-12","current":-24.897804,"twenty":-55.858362,"median":-45.508136,"eighty":-26.138816,"marketCap":94519037},{"date":"2025-12-19","current":-23.268976,"twenty":-55.63931,"median":-44.029532,"eighty":-25.595874,"marketCap":88335549},{"date":"2025-12-26","current":-23.036286,"twenty":-55.464068,"median":-42.496165,"eighty":-24.137684,"marketCap":87452193},{"date":"2026-01-02","current":-30.559922,"twenty":-54.828816,"median":-32.964383,"eighty":-24.075634,"marketCap":116014021},{"date":"2026-01-09","current":-36.066913,"twenty":-54.30309,"median":-35.136154,"eighty":-24.292811,"marketCap":136920100},{"date":"2026-01-16","current":-37.385488,"twenty":-54.149753,"median":-35.834223,"eighty":-24.680627,"marketCap":141925782},{"date":"2026-01-23","current":-36.687419,"twenty":-53.711649,"median":-35.834223,"eighty":-25.083956,"marketCap":139275715},{"date":"2026-01-30","current":-33.740015,"twenty":-52.638292,"median":-35.911787,"eighty":-25.45626,"marketCap":128086546},{"date":"2026-02-06","current":-28.698404,"twenty":-50.513483,"median":-35.446407,"eighty":-25.69184,"marketCap":108947177},{"date":"2026-02-13","current":-27.806427,"twenty":-48.322959,"median":-35.097373,"eighty":-25.925975,"marketCap":105560981},{"date":"2026-02-20","current":-26.371506,"twenty":-48.027239,"median":-33.584888,"eighty":-25.643857,"marketCap":100113622},{"date":"2026-02-27","current":-29.784289,"twenty":-47.359128,"median":-32.809256,"eighty":-25.86537,"marketCap":113069502},{"date":"2026-03-06","current":-26.21638,"twenty":-47.161981,"median":-31.723371,"eighty":-25.999203,"marketCap":99524718},{"date":"2026-03-13","current":-28.892312,"twenty":-46.395298,"median":-30.559922,"eighty":-26.076766,"marketCap":109683306},{"date":"2026-03-20","current":-26.604196,"twenty":-45.672425,"median":-29.706726,"eighty":-26.154329,"marketCap":100996977},{"date":"2026-03-27","current":-26.371506,"twenty":-45.1467,"median":-28.892312,"eighty":-26.154329,"marketCap":100113622},{"date":"2026-04-02","current":-24.160954,"twenty":-44.796216,"median":-28.775967,"eighty":-25.98369,"marketCap":91721745},{"date":"2026-04-10","current":-32.734315,"twenty":-44.029532,"median":-28.989266,"eighty":-26.061253,"marketCap":104556020},{"date":"2026-04-17","current":-31.894973,"twenty":-43.81048,"median":-29.784289,"eighty":-26.138816,"marketCap":101875096},{"date":"2026-04-24","current":-31.242152,"twenty":-42.496165,"median":-30.559922,"eighty":-26.21638,"marketCap":99789934},{"date":"2026-05-01","current":-34.415795,"twenty":-38.471374,"median":-30.882559,"eighty":-26.371506,"marketCap":109926804},{"date":"2026-05-08","current":-35.392229,"twenty":-38.238684,"median":-31.242152,"eighty":-26.371506,"marketCap":113045611},{"date":"2026-05-15","current":-31.212763,"twenty":-37.850868,"median":-31.242152,"eighty":-26.44907,"marketCap":119747920},{"date":"2026-05-22","current":-38.588913,"twenty":-38.045407,"median":-31.288782,"eighty":-26.44907,"marketCap":148046558},{"date":"2026-05-29","current":-41.228799,"twenty":-38.837373,"median":-31.468187,"eighty":-26.480095,"marketCap":158174492},{"date":"2026-06-05","current":-44.606299,"twenty":-41.306443,"median":-31.521933,"eighty":-26.518877,"marketCap":171132289},{"date":"2026-06-12","current":-45.499201,"twenty":-41.792847,"median":-31.925517,"eighty":-26.588683,"marketCap":174557914},{"date":"2026-06-18","current":-46.819144,"twenty":-43.898101,"median":-32.128124,"eighty":-26.604196,"marketCap":179621881},{"date":"2026-06-26","current":-52.952995,"twenty":-44.973973,"median":-32.641055,"eighty":-26.650734,"marketCap":203154432},{"date":"2026-07-02","current":-53.185927,"twenty":-45.699909,"median":-32.809256,"eighty":-26.681759,"marketCap":204048074},{"date":"2026-07-10","current":-68.40409,"twenty":-46.788086,"median":-33.107355,"eighty":-26.74381,"marketCap":262432632},{"date":"2026-07-17","current":-70.112251,"twenty":-47.348176,"median":-33.573656,"eighty":-26.867911,"marketCap":268986001},{"date":"2026-07-24","current":-73.606217,"twenty":-48.853305,"median":-34.461027,"eighty":-26.945474,"marketCap":282390619},{"date":"2026-07-31","current":-64.056043,"twenty":-51.501785,"median":-34.552888,"eighty":-26.992012,"marketCap":245751330},{"date":"2026-08-07","current":-74.615585,"twenty":-53.558617,"median":-35.327878,"eighty":-27.007525,"marketCap":286263064},{"date":"2026-08-14","current":-34.775161,"twenty":-54.193564,"median":-35.356755,"eighty":-27.085088,"marketCap":293710074},{"date":"2026-08-21","current":-33.646556,"twenty":-54.04617,"median":-35.233657,"eighty":-27.147139,"marketCap":284177901},{"date":"2026-08-28","current":-35.656885,"twenty":-53.776019,"median":-34.888704,"eighty":-27.147139,"marketCap":301157084},{"date":"2026-08-31","current":-34.704623,"twenty":-53.744961,"median":-34.825901,"eighty":-27.147139,"marketCap":293114313}],"updateTime":1788321805612},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640969988","title":"Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2640969988","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640969988?lang=en_us&edition=fundamental","pubTime":"2026-06-02 02:30","pubTimestamp":1780338600,"startTime":"0","endTime":"0","summary":"Turn Therapeutics shares were higher after the company reported favorable interim results from an eczema study with its lead drug candidate, GX-03.The stock rose 28% to $6.65 Monday and is up about 69% this year.Turn Therapeutics reported findings from the first 50 completed subjects enrolled in the Phase 2 clinical trial.Within the completed interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in overall eczema severity within four weeks compared to 65.2% for vehicle-treated subjects, the company said. GX-03 continued to demonstrate a favorable safety and tolerability profile.\"What became increasingly apparent during the interim review was the speed with which responses emerged,\" the company said. It said \"The consistency of response across earlier efficacy measures suggests clinically meaningful improvement may emerge sooner than originally anticipated, which could have important implications for both future regulatory strategy and patient outcomes.\". The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","TTRX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968956","title":"Turn announces interim analysis findings from Phase 2 trial of GX-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968956?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:54","pubTimestamp":1780325675,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-announces-interim-analysis-findings-from-phase-2-trial-of-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-announces-interim-analysis-findings-from-phase-2-trial-of-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957153","title":"Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640957153?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:46","pubTimestamp":1780321572,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has shared an announcement. On June 1, 2026, Turn Therapeutics reported interim results from the first 50 complet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-reports-positive-interim-phase-2-gx-03-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-reports-positive-interim-phase-2-gx-03-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TTRX","BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640432951","title":"Turn Therapeutics says Phase 2 interim data show GX-03 hits 70.4% EASI-75 at week 4 in atopic dermatitis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640432951","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640432951?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317050,"startTime":"0","endTime":"0","summary":"Turn Therapeutics released interim Phase 2 results for topical GX-03 in adults with moderate-to-severe atopic dermatitis.The analysis showed faster, more substantial symptom improvement versus vehicle, with benefits deepening over the treatment period.Safety looked favorable, with no treatment-related serious adverse events or treatment-related discontinuations reported in the interim cohort.The readout prompted changes to enrollment criteria and endpoint priorities to sharpen the second stage of the ongoing trial.More detailed findings will be presented at the Jefferies Global Healthcare conference on June 4, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6rbjMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951973","title":"Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy From Phase 2 Gx-03 Trial in Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951973?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6FMCWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951204","title":"Turn Therapeutics - Interim Analysis Leads to Trial Enrollment and Endpoint Refinement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951204?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6FMCWT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640512079","title":"Turn Therapeutics - No Treatment-Related Serious Adverse Events or Discontinuations Reported in Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640512079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640512079?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6FMCWT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689194","title":"Turn Therapeutics announces peer-reviewed article on GX-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638689194?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:27","pubTimestamp":1779892077,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the ef...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-announces-peer-reviewed-article-on-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-announces-peer-reviewed-article-on-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","BK4539","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507056","title":"Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507056?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:07","pubTimestamp":1779883646,"startTime":"0","endTime":"0","summary":"Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment. Turn Therapeutics flagged peer-reviewed results already published on GX-03 in an IL-36-associated murine dermatitis model.The study showed GX-03 reduced visible disease severity versus no treatment, supporting activity in an inflammation setting linked to skin barrier disruption.No treatment-related safety issues were observed in the animal study.The publication underpins GX-03’s Phase 2 program in moderate-to-severe atopic dermatitis, supporting a localized, non-systemic development strategy.A follow-on mechanistic manuscript is under review, with additional publications planned.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5YfDD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636011859","title":"Turn Therapeutics CEO to Present at Jefferies Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2636011859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636011859?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:46","pubTimestamp":1779194770,"startTime":"0","endTime":"0","summary":"The latest update is out from Turn Therapeutics Inc ( ($TTRX) ). On May 19, 2026, Turn Therapeutics Inc. announced that Chief Executive Officer Bra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-ceo-to-present-at-jefferies-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-ceo-to-present-at-jefferies-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","TTRX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885577","title":"Turn Therapeutics CEO presents at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636885577?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:07","pubTimestamp":1779192470,"startTime":"0","endTime":"0","summary":"Turn Therapeutics will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026.Chief Executive Officer Bradley Burnam is scheduled to speak from 9:55 a.m. to 10:25 a.m. EDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL4B1Q1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636760120","title":"Turn Therapeutics Appoints Former FDA Chief to Lead GX-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2636760120","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636760120?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:16","pubTimestamp":1779110178,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has shared an update. Turn Therapeutics Inc., a clinical-stage biotechnology company listed on Nasdaq, develops t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-appoints-former-fda-chief-to-lead-gx-03?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-appoints-former-fda-chief-to-lead-gx-03?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4585","NQmain","DBB","TTRX","BK4007","BK4139","LABU","LENZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636734290","title":"Turn appoints Hahn as Executive Clinical, Regulatory Lead for GX-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2636734290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636734290?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:19","pubTimestamp":1779106798,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) announced the appointment of Stephen Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration, FDA, to ove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-appoints-hahn-as-executive-clinical-regulatory-lead-for-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-appoints-hahn-as-executive-clinical-regulatory-lead-for-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588","DBB","BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073587","title":"Turn Therapeutics names former FDA chief Hahn executive clinical, regulatory lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073587","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073587?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:05","pubTimestamp":1779105948,"startTime":"0","endTime":"0","summary":"Turn Therapeutics appointed former U.S. Food and Drug Administration Commissioner Stephen M. Hahn as executive clinical and regulatory lead.Hahn will oversee clinical and regulatory strategy for GX-03, an investigational topical therapy in a Phase 2 trial for moderate-to-severe atopic dermatitis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL68tFXd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634713255","title":"BRIEF-Turn Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634713255","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634713255?lang=en_us&edition=fundamental","pubTime":"2026-05-12 06:39","pubTimestamp":1778539155,"startTime":"0","endTime":"0","summary":"BRIEF-Turn Therapeutics Reports First Quarter 2026 Financial Results May 11 (Reuters) - Turn Therapeutics Inc TTRX.O:TURN THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5VKGKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634723024","title":"Turn Therapeutics posts corporate presentation on GX-03 topical immunomodulator for atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2634723024","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634723024?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:40","pubTimestamp":1778532053,"startTime":"0","endTime":"0","summary":"Turn Therapeutics highlighted lead topical candidate GX-03, a non-systemic IL-36/IL-31 inhibitor program for moderate-to-severe atopic dermatitis, with a Phase 2 randomized controlled trial underway and topline data expected mid-2026.Phase 2 design calls for about 120 patients, with an adaptive option to expand to 200; primary endpoint is change in IGA score versus vehicle at week 8.Presentation cited more than 200,000 patients previously receiving GX-03 in other cleared uses, with zero reported adverse events, including a 53-patient RIPT study that reported no adverse reactions across more than 580 applications.Management outlined a development path targeting Phase 3 initiation in 2027, with a planned GX-03 launch in 2029, subject to trial outcomes and capital availability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8psg0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634273232","title":"Turn Therapeutics Q1 FY26 net loss widens to $970,972; G&A expenses rise to $1.14 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634273232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634273232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:07","pubTimestamp":1778530037,"startTime":"0","endTime":"0","summary":"Turn Therapeutics posted a net loss of USD 970,972, or USD 0.03 per share, for three months ended March 31, 2026, versus a net loss of USD 328,547, or USD 0.01 per share, a year earlier.Operating loss widened to USD 1.25 million as total operating expenses climbed to USD 1.25 million; G&A rose to USD 1.14 million.Cash and cash equivalents increased to USD 11.2 million at March 31, 2026, following funding of an initial USD 7 million tranche under a growth capital facility providing access to up to USD 25 million in term loans.Phase 2 trial of GX-03 in moderate-to-severe atopic dermatitis remained on track, with interim results expected in Q2 2026 and topline data expected mid-2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL6WXKJd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634322822","title":"Press Release: Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634322822","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634322822?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"Phase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis  on Track, Topline Results Expected Mid-2026. Initial Tranche of $7 Million in Growth Capital has been Funded by Avenue Capital Group. Turn Therapeutics Inc. , a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates.\"The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially,\" said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. \"With the Avenue Capital facility now in place, we believe the Company is well positioned to advance our clinical programs through multiple near-term catalysts while maintaining focus on disciplined execution. Our Phase 2 trial evaluating GX-03 in moderate-to-severe atopic dermatitis remains on schedule, with an independent committee expected to assess conditional ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4007","BK4132","BK4539","BK4139","LENZ","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624371835","title":"Turn Therapeutics FY25 net loss widens to $3.2 million; G&A expenses climb to $5.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624371835","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624371835?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:08","pubTimestamp":1774987738,"startTime":"0","endTime":"0","summary":"Turn Therapeutics posted a net loss of USD 3.2 million for 2025.Operating loss widened to USD 5.9 million as total operating expenses rose to USD 5.9 million.Cash and cash equivalents climbed to USD 5.1 million as of Dec. 31, excluding USD 7 million in gross proceeds from Avenue Capital.Avenue Capital provided a venture debt facility of up to USD 25 million, including an initial USD 7 million tranche, extending expected cash runway through end-2027.Management said Phase 2 GX-03 atopic dermatitis topline results remain on track for mid-2026, with a Medline agreement expected to enable revenue generation in late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5h1CrG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067940","title":"Turn Therapeutics Secures Growth Capital to Advance Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067940","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067940?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:50","pubTimestamp":1774356606,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has issued an update. On March 23, 2026, Turn Therapeutics Inc. entered into a secured growth capital loan facili...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-secures-growth-capital-to-advance-dermatology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-secures-growth-capital-to-advance-dermatology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","TTRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}